PALO ALTO, Calif., June 11 /PRNewswire-FirstCall/ -- Avicena Group, Inc. , a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today that Avicena with its collaborator, SunnyBioDiscovery will co- present at the Strategic Research Institute’s (SRI) 4th Annual Cosmeceuticals Conference on June 12, 2007 at 11:30 a.m. EDT at the Marriott Eastside Hotel in New York City. Bolko Stolberg, Vice President, Marketing and Strategy, of Avicena and co-presenter, Krys Bojanowski, Ph.D., CEO of Sunny Biodiscovery, will discuss the benefits of creatine ascorbate, a new dermaceutical compound available to the personal care industry.
“We are delighted to have this opportunity to highlight our dermaceutical business,” stated Belinda Tsao-Nivaggioli, CEO of Avicena. “At Avicena, we have leveraged our proprietary cellular energy modulation technology to develop novel multi-targeted ingredients and formulations that provide enhanced performance and incremental benefits for the consumer.”
For more information on SRI 4th Annual Cosmeceuticals Conference please visit www.srinstitute.com.
ABOUT AVICENA’S DERMACEUTICAL BUSINESS
Avicena is leveraging its proprietary cellular energy technology to commercialize therapeutic dermaceutical products, as well as proprietary ingredients and formulations. Avicena’s skin care ingredients and formulations are designed to enhance the regeneration of healthy skin and to protect against the effects of aging, as well as oxidative and photo damage.
Avicena has developed Nurigene, a scientifically advanced skin care product line based on the company’s proprietary cellular energy platform. The Nurigene skin care regimen incorporates Avicena’s patented advanced cell nourishing technology which promotes optimal cellular regeneration and protection by providing critical nourishment to the skin’s cellular growth environment. Clinical studies have demonstrated that Nurigene leads to significant improvements in skin cell turnover, skin firmness, skin elasticity and the skin’s ability to retain moisture.
Avicena also currently supplies its patent-protected ingredients to leading manufacturers of dermaceutical and cosmeceutical products. Avicena is also actively researching and developing additional proprietary formulations to complement its current dermaceutical product portfolio.
ABOUT AVICENA
Avicena Group, Inc. is a late stage biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes. The company’s core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena’s pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. Near term, Avicena intends to initiate a Phase III trial in Huntington’s disease to accompany the ongoing Phase III trial in Parkinson’s disease. Avicena’s science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena’s clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.
SAFE HARBOR
This release contains forward-looking statements that reflect, among other things, management’s current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See “Risk Factors” under “Item 6. Management’s Discussion and Analysis of Financial Condition and Results of Operation” from our Annual Report on Form 10-KSB for the year ended December 31, 2006, and other descriptions in the company’s public filings with the Securities and Exchange Commission for a discussion of such risks, including the company’s need for additional funds, the company’s dependence on a limited number of therapeutic compounds, the stage of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company’s ability to avoid infringement of the patent rights of others, and the company’s ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Avicena does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.
Contact: The Ruth Group (on behalf of Avicena Group) Stephanie Carrington / Sara Ephraim / (investors) (646) 536-7017 / 7002 scarrington@theruthgroup.com or sephraim@theruthgroup.com Janine McCargo / Jason Rando (media) (646) 536-7033 / 7025 jmccargo@theruthgroup.com or jrando@theruthgroup.com
Avicena Group, Inc.
CONTACT: investors, Stephanie Carrington, +1-646-536-7017,scarrington@theruthgroup.com, Sara Ephraim, +1-646-536-7002,sephraim@theruthgroup.com or media, Janine McCargo, +1-646-536-7033,jmccargo@theruthgroup.com, or Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, of The Ruth Group, on behalf of Avicena Group
Web site: http://www.srinstitute.com/
